Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: AurumRabosa who wrote (417)	2/15/2000 4:33:00 PM
From: Skywatcher	Respond to of 1137

NO look at almost all the other biotechs that don't even HAVE REVENUES... that's the key VPHM, TRMS, ETC.... no earnings...sky high prices. SCLN...rev's growing OVER 25% per quarter less than $10 chris

To: AurumRabosa who wrote (417)	2/15/2000 9:41:00 PM
From: 5handicap	Read Replies (1) \| Respond to of 1137

Ron, VRTX P/S 30 Mkt Cap=1.3 Billion year earnings -2.00 eps dec00 AVAN P/S 150, Mkt Cap=435 M ARIA P/S 29 Mkt Cap=370 M year earnings -0.64 eps dec00 NPSP P/S 59 Mkt Cap=215 M year earnings -0.83 eps dec00 TXB P/S 200 Mkt Cap=440 M year earnings -0.00 eps dec00 I could keep going, but I guess you get the drift.... if you know of a company with as much potential as Sciclone that is a better buy, I'm interested. Chris C. -- I changed my login to match ragingbull-- Rocky

To: AurumRabosa who wrote (417)	2/16/2000 3:47:00 PM
From: 5handicap	Read Replies (2) \| Respond to of 1137

TheStreet.com has come out with their list of biotechs. Maybe they should call it their list of the most overpriced biotechs. Take a look and compare to Sciclone, ticker.. P/S .. Mkt Cap (Billion$) AMGN...21. 66.5 IMNX...51.. 25.6 MEDI...31.. 10.8 CRA....288 .. 6.9 MLNM...44 .. 8.0 ABGX...450 .. 4.7 ALKS... 78 .. 3.0 CRGN... 167 .. 2.8 VRTX... 30 .. 1.35 IMCL...1000 .. 2.2 DNA.... 30 .. 43 BGEN... 20 .. 15.1 AFFX... 67 .. 6.8 HGSI... 290 .. 7.0 INCY... 35 .. 5.6 INHL... 41 .. 1.4 IDPH... 50 .. 4.9 GENZ... 7 .. 4.4 PDLI... 95 .. 3.2 TKTX... 220 .. 1 And now for the drum roll.. SCLN... 20 .. 0.2 (and I note that the present year P/S is about 12, and sales are growing at over 100%/year. I just used the yahoo figure of 20 to be consistent, since I got all the other data from yahoo profiles) Sciclone is under-priced. I doubt it will stay that way for long in this biotech hungry market.